Incyte Co. (NASDAQ:INCY - Free Report) - Stock analysts at William Blair upped their Q1 2025 EPS estimates for shares of Incyte in a research note issued to investors on Tuesday, April 23rd. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings per share of $0.90 for the quarter, up from their prior forecast of $0.71. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Incyte's current full-year earnings is $3.85 per share.
Incyte (NASDAQ:INCY - Get Free Report) last posted its earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 EPS for the quarter, missing analysts' consensus estimates of $1.15 by ($0.09). Incyte had a return on equity of 12.56% and a net margin of 16.17%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the firm posted $0.44 EPS. The company's revenue for the quarter was up 9.3% on a year-over-year basis.
Several other research firms have also commented on INCY. Oppenheimer lowered their price objective on shares of Incyte from $92.00 to $84.00 and set an "outperform" rating for the company in a research report on Wednesday. Citigroup lowered their price target on shares of Incyte from $82.00 to $81.00 and set a "buy" rating for the company in a report on Wednesday, February 14th. BMO Capital Markets upped their price objective on Incyte from $58.00 to $64.00 and gave the company a "market perform" rating in a research report on Wednesday, February 14th. Stifel Nicolaus lifted their target price on Incyte from $67.00 to $68.00 and gave the stock a "hold" rating in a report on Wednesday, February 14th. Finally, Truist Financial decreased their price target on Incyte from $91.00 to $84.00 and set a "buy" rating on the stock in a report on Wednesday, February 14th. Nine research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $75.50.
View Our Latest Research Report on Incyte
Incyte Price Performance
Shares of INCY traded down $0.56 during mid-day trading on Thursday, hitting $51.18. 1,771,930 shares of the stock were exchanged, compared to its average volume of 1,725,502. The firm has a 50-day moving average of $57.06 and a two-hundred day moving average of $57.78. Incyte has a 52-week low of $50.27 and a 52-week high of $75.74. The company has a market cap of $11.49 billion, a PE ratio of 19.06, a price-to-earnings-growth ratio of 1.19 and a beta of 0.65. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.36 and a current ratio of 3.55.
Institutional Trading of Incyte
Several hedge funds and other institutional investors have recently made changes to their positions in INCY. Cape Investment Advisory Inc. purchased a new stake in Incyte during the 4th quarter worth approximately $25,000. Larson Financial Group LLC grew its holdings in shares of Incyte by 4,220.0% during the fourth quarter. Larson Financial Group LLC now owns 432 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 422 shares during the last quarter. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Incyte in the 4th quarter valued at $31,000. Redmont Wealth Advisors LLC acquired a new position in shares of Incyte in the 1st quarter valued at $28,000. Finally, Riverview Trust Co acquired a new stake in Incyte during the 1st quarter worth about $29,000. Hedge funds and other institutional investors own 96.97% of the company's stock.
About Incyte
(
Get Free Report)
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
See Also
Before you consider Incyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.
While Incyte currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
